This study describes the effects of streptozocin (STZ)-induced diabetes mellitus on the glucose-transporter system of the rat blood-brain barrier. Subcellular membrane fractions, i.e., plasma membranes and high-and low-density microsomes, were prepared from isolated brain microvessels derived from control and diabetic animals. The number of glucose transporters in each of the membrane fractions from both control and diabetic animals was determined by the D-glucose-inhibitable cytochalasin B-binding assay. The total number of glucose transporters was decreased by 43% in STZ-treated rats compared with controls (35 vs. 115 pmol/mg protein; P < .05). The glucose-transporter number in plasma membranes was decreased by 50%, in highdensity microsomes by 38%, and in low-density microsomes by 45%. Incubation of isolated microvessels from control animals with 7 jiM insulin for 30 min at 37°C led to a cycloheximide-sensitive 27% increase (P < .05) in the number of transporters in high-density microsomes. This insulin effect was significantly diminished to 15% in the diabetic animals (P < .05). In conclusion, 1) STZ-induced diabetes decreases the glucose-transporter number in all subcellular membrane fractions derived from isolated rat brain microvessels, and 2) the insulin-induced increase in de novo synthesis of glucose transporters in brain microvessels is diminished in these chronically diabetic animals. DIABETES 1986; 35:1181-84.
occurs in diabetics when plasma glucose values fall to hypoglycemic levels, and it has been suggested that relative cerebral hypoglycemia can occur in the absence of chemical hypoglycemia, when glucose levels drop from hyperglycemic to euglycemic values; this suggests insufficient capacity for glucose transport across the blood-brain barrier. 56 Indeed, with different methodologies, i.e., extraction of labeled glucose from brain, glucose conversion to CO 2 , and the Oldendorf brain uptake index method, it has been shown that the maximum in vivo transport capacity for glucose is decreased in chronically hyperglycemic animals. 7 " 9 To gain insight into the cellular events accompanying this phenomenon, we investigated the effects of streptozocin (STZ)-induced insulin-deficient diabetes mellitus on the number and subcellular distribution of glucose transporters at the bloodbrain barrier.
MATERIALS AND METHODS
One hundred thirty-three male Sprague-Dawley rats were divided into two groups. The experimental group was rendered hyperglycemic by a single injection of STZ (50 mg/kg body wt i.p.). Both groups ate rat chow ad libitum and were housed in the same way for 4 wk. Plasma glucose levels and other parameters were measured and are shown in Table 1 . The animals were decapitated, and microvessels from cortex were prepared by a modification 10 of the method of Goldstein et al. 11 according to the following procedure. Subcellular membrane fractions from isolated microvessels were also prepared according to the following procedure. After isolation from cerebral cortex microvessels were centrifuged at 500 x g max for 5 min. 5 ' 6 The resulting pellet was resuspended in ice-cold 20 mM Tris, 1 mM EDTA, and 250 mM sucrose (TES) buffer, pH 7.4, containing 2.5 |xg/ml aprotinin, leupeptin, and pepstatin. The microvessels were homogenized by sonication ( 2 x 2 min) on ice with a Branson model 200 cell disruptor (Heat Systems-Ultrasonics, Farmingdale, KY). The resulting homogenate was centrifuged at 17,000 x g max for 30 min. The supernatant was saved for the preparation of microsomal membrane fractions. The pellet, which contained plasma membranes and mitochondria, was resuspended into TES buffer, layered on a Tris (20 mM) plus EDTA (1 mM) plus 4 1 % sucrose cushion, and centrifuged at 101,000 x g max for 1 h. Plasma membranes, which band at the 4 1 % sucrose-TES interface, were collected by aspiration with a Pasteur pipette and diluted with TES buffer. The purified plasma membranes were pelleted by centrifugation at 48,000 x c/ max f°r 45 min. The resulting pellet was washed in TES buffer and collected by centrifugation at 17,000 x g max for 30 min. The plasma membranes were resuspended in TES and stored at -80°C. The initial supernatant was centrifuged at 48,000 x g max for 30 min, yielding a pellet of high-density microsomes. The supernatant was then centrifuged at 430,000 x g max for 90 min, yielding a pellet of low-density microsomes. All pellets were resuspended in TES buffer, pH 7.4, and stored at -80°C. Protein was determined by the method of Lowry et al. 14 as modified by Peterson. 15 Sodium fluoride-stimulated adenylate cyclase activity was measured by the method of Salomon et al. 16 Rotenone-insensitive NADH-cytochrome c reductase activity was determined by the method of Dallner et al. 17 Nacetyllactosamine synthase activity was determined by the method of Fleisher.
18 Phase-contrast microscopy revealed that the isolated microvessels were virtually free of contamination by glial or neuronal tissue. Alkaline phosphatase, which is primarily located within capillaries, was measured in microvessel preparations, 12 and enzyme activity was enriched 25 ± 1.2-fold (mean ± SE, N = 3) when compared with the cerebral cortex homogenate; these values are comparable with those reported in the literature. 1113 As described elsewhere (S. Matthaei, J. M. Olefsky, T. W. Garvey, and R. Horuk, unpublished observations), compared with homogenate, the membrane-fractionation method leads to ~33-fold enrichment in adenylate cyclase in plasma membranes, -2 1 -fold increase in cytochrome c reductase in high-density microsomes, and ~6.5-fold increase in galactosyltransferase activity in low-density microsomes.
The number of D-glucose-inhibitable cytochalasin B-binding sites in the subcellular fractions was determined as previously described.
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RESULTS
By measuring D-glucose (500 mM)-inhibitable [
3 H]cytochalasin B binding to the membrane fractions, 20 we estimated the number of glucose transporters in brain microvessel subcellular fractions from both control and STZ-induced diabetic rats with Scatchard plots of the [ 3 H]cytochalasin B-binding data. The results shown in Fig. 1 45% in low-density microsomes (P < .05). The number of glucose transporters in all membrane fractions combined was decreased by 43% (115 pmol/mg protein in controls vs. 35 pmol/mg protein in STZ-treated animals; P < .05).
As seen in Fig. 2 , incubation of isolated microvessels from control animals with 7 nM insulin for 30 min at 37°C did not significantly alter the number of glucose transporters in plasma membranes and low-density microsomes but did increase the number of transporters in high-density microsomes by 27% (P < .05). Pretreatment of microvessels with cycloheximide (10 |xg/ml) for 60 min before insulin completely inhibited the increase in high-density microsome [ 3 H]cytochalasin B-binding sites ( Table 2 ), suggesting that this effect of insulin involved de novo synthesis of glucose transporters. Figure 2 also shows that the stimulatory effect of insulin to increase high-density microsome glucose transporters was blunted in the STZ-induced diabetic animals. Insulin induces a slight increase in the number of glucose transporters in high-density microsomes from the diabetic animals, but the increase is significantly lower than in control high-density microsomes (27% increase in controls vs. 15% in diabetic rats; P < .05). Insulin treatment did not significantly alter the dissociation constant (K D ) for [ 
DISCUSSION
Karnieli et al. 22 investigated the effects of STZ-induced diabetes mellitus on the glucose-transporter system in isolated rat adipocytes. In adipocytes, insulin stimulates glucose transport by inducing a rapid and reversible translocation of glucose transporters from an intracellular membrane pool associated with the low-density microsomal fraction to the plasma membrane. 2021 Karnieli et al. 22 found a depletion of glucose transporters in the low-density microsomes consistent with the decrease in fat cell glucose-transport activity and the insulin resistance in these animals. Betz et al. 23 have shown that insulin did not acutely stimulate 3-O-methylglucose uptake by isolated brain microvessels. We have confirmed these results using 2-deoxyglucose as substrate (data not shown). Thus, insulin does not appear to have an acute effect on glucose uptake at the blood-brain barrier.
The findings presented here indicate that in the basal state, there are already many glucose carriers on the cell surface, and insulin does not acutely alter the subcellular distribution of transporters. However, insulin appears to stimulate de novo synthesis of glucose transporters in brain microvessels, as shown by the insulin-mediated increase in high-density microsome glucose transporters. This effect is diminished in the diabetic state and may underlie the decreased number of transporters in microvessel membrane fractions from these animals. The depletion of blood-brain glucose transporters is consistent with earlier in vivo studies that showed decreased brain glucose uptake and metabolism in experimental diabetic animals. 7 -9 Whether it is the insulin deficiency, the hyperglycemia, both together, or some other aspect of the chronic diabetic state that leads to decreased brain microvessel glucose transporters cannot be determined from current studies. However, we favor the role of insulin deficiency, because non-insulin-mediated glucose uptake (predominantly central nervous system) is normal in hyperglycemic non-insulin-dependent diabetic subjects, 24 as are estimates of brain glucose extraction in insulin-treated but still hyperglycemic subjects. 25 We conclude that STZ causes a diabetic state associated with fewer glucose-transport proteins in brain microvessels, which may result in reduced capacity of glucose transfer across the blood-brain barrier. This phenomenon may contribute to the development of neuroglycopenia in diabetes.
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